Wakefulness-Promoting Agents

A specific category of drugs that prevent sleepiness by specifically targeting sleep-mechanisms in the brain. They are used to treat DISORDERS OF EXCESSIVE SOMNOLENCE such as NARCOLEPSY. Note that this drug category does not include broadly-acting central nervous system stimulants such as AMPHETAMINES.

Also Known As:

Eugeroic Drugs; Wake-Promoting Drugs; Wake-Promoting Substances; Agents, Wake-Promoting; Agents, Wakefulness-Promoting; Drug, Wake-Promoting; Drugs, Eugeroic; Drugs, Wake-Promoting; Substances, Wake-Promoting; Wake Promoting Agents; Wake Promoting Drug; Wake Promoting Drugs; Wake Promoting Substances; Wakefulness Promoting Agents; Wake-Promoting Agents; Wake-Promoting Drug

Networked: 72 relevant articles (8 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Central Nervous System Agents: 51
      - Central Nervous System Stimulants: 455
        Wakefulness-Promoting Agents: 72

Experts

1.	Dauvilliers, Yves: 3 articles (01/2019 - 08/2017)
2.	Tufik, Sergio: 3 articles (02/2018 - 10/2011)
3.	Ishizuka, Tomoko: 3 articles (01/2012 - 03/2003)
4.	Yamatodani, Atsushi: 3 articles (01/2012 - 03/2003)
5.	Abad, Vivien C: 2 articles (01/2021 - 07/2019)
6.	Pérez-Carbonell, Laura: 2 articles (01/2020 - 11/2019)
7.	Barateau, Lucie: 2 articles (01/2019 - 08/2017)
8.	Ogeil, Rowan P: 2 articles (01/2019 - 01/2018)
9.	Rye, David B: 2 articles (01/2019 - 03/2006)
10.	Andersen, Monica Levy: 2 articles (02/2018 - 02/2018)

Related Diseases

1.	Disorders of Excessive Somnolence (Hypersomnia) 05/01/2023 - "Annals Video Summary - Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With OSA." 01/01/2018 - "Our results indicate that NLS-4 is a highly potent wake-promoting drug with no sign of hypersomnia rebound. " 11/01/2009 - "Rebound hypersomnolence (RHS: increased sleep following increased wake) is a limiting side-effect of many wake-promoting agents. " 06/01/2009 - "Wake-promoting drugs are widely used to treat excessive daytime sleepiness. " 01/01/2023 - "Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis."
2.	Sleepiness 01/01/2018 - "Interactions between night-shift work and wake-promoting drug use were also found for excessive sleepiness. " 10/15/2015 - "Wakefulness promoting agents improve objective and subjective measures of sleepiness, wakefulness, perception of disease severity in patients with residual sleepiness after CPAP therapy for OSA, and are generally well tolerated." 08/01/2013 - "Residual symptoms are not limited to sleepiness, suggesting a true 'continuous positive airway pressure-resistant syndrome', which may justify treatment by wake-promoting drugs." 08/01/2013 - "Although continuous positive airway pressure may not be fully efficient in treating this symptom, wake-promoting drug prescription in residual excessive sleepiness is no longer allowed by the European Medicines Agency. " 01/01/2020 - "Refractory daytime sleepiness was defined as an Epworth sleepiness scale (ESS) score >12 despite trialling at least three wakefulness-promoting agents. "
3.	Schizophrenia (Dementia Praecox) 03/01/2012 - "Modafinil is a wake-promoting drug that has been shown to improve attention, memory and executive function in the healthy population and in patients with schizophrenia. " 03/01/2011 - "Modafinil is a wake-promoting drug that has been shown to improve emotion discrimination in healthy individuals and attention and executive function in schizophrenia. "
4.	Narcolepsy 01/01/2023 - "The current study systematically updates the comparative efficacy and detailed safety analysis of approved wake-promoting agents in narcolepsy. " 01/01/2020 - "We assessed adherence to wakefulness-promoting agents in narcolepsy patients. " 01/01/2019 - "Narcolepsy is an active area for drug development, and new wake-promoting agents have been developed over the past years. " 02/01/2018 - "Most of other wakefulness-promoting agents labeled for narcolepsy have similar efficacy in cases series of IH patients. " 01/01/2023 - "Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis."
5.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 12/01/2015 - "Modafinil is a wake-promoting drug with FDA approval for the treatment of excessive daytime sleepiness that has been prescribed for ADHD and recently assessed as a potential treatment for psychostimulant dependence. " 01/01/2008 - "With regard to the therapeutic implications, we suggest that wake-promoting agents with anorexigenic effect, such as mazindol, might be particularly indicated for the treatment of ADHD symptoms in obese patients, since they might address both ADHD symptoms and weight reduction. " 01/01/2000 - "Our objective was to compare the efficacy of the new wake-promoting drug modafinil to that of dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. " 03/01/2002 - "A systematic review of the literature identified 15 studies (N = 435 subjects) of stimulants, and 22 studies of non-stimulant medications (N = 421 subjects) including antidepressants, antihypertensives, amino acids, and wake-promoting agents for the treatment of ADHD in adults. " 01/01/2003 - "Although the use of pharmacotherapy in children with ADHD is well studied, the use of drugs for the treatment of adults with ADHD remains less well established.A systematic review of the literature identified 15 studies (n = 482 patients) of stimulants, and 27 studies of nonstimulant medications (n = 1179 subjects) including antidepressants, norepinephrine reuptake inhibitors, antihypertensive agents, amino acids and wake-promoting agents for the treatment of ADHD in adults. "

Related Drugs and Biologics

1.	Modafinil (Provigil)
2.	Antidepressive Agents (Antidepressants)
3.	Methylphenidate (Ritalin)
4.	Amphetamines
5.	Sodium Oxybate (gamma Hydroxybutyrate)
6.	Dextroamphetamine (Dexedrine)
7.	Venlafaxine Hydrochloride (Effexor)
8.	Antihypertensive Agents (Antihypertensives)
9.	Amino Acids
10.	solriamfetol

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Continuous Positive Airway Pressure